Stockholm (HedgeNordic) – Healthcare-focused asset manager Rhenman & Partners has promoted its two analysts, Hugo Schmidt and Amennai Beyeen, to the position of Portfolio Managers. The freshly promoted portfolio managers oversee the asset manager’s healthcare-focused long-biased equity hedge fund alongside portfolio manager Kaspar Hållsten and Henrik Rhenman, who serves as the CIO.
“I am excited to announce the promotions of Hugo Schmidt and Amennai Beyeen to Portfolio Managers at Rhenman & Partners,” Henrik Rhenman, co-founder and CIO at Rhenman & Partners, expresses his enthusiasm for the promotions. “Hugo and Amennai both have a deep understanding of the healthcare market, its dynamics and trends. Their commitment to their work and how they strive to find today’s and future winners within the space is remarkable, so these promotions are very well deserved by both.”
“I am excited to announce the promotions of Hugo Schmidt and Amennai Beyeen to Portfolio Managers at Rhenman & Partners.”
Henrik Rhenman
Each of the three portfolio managers specializes in different healthcare sub-sectors. Kaspar Hållsten focuses on the MedTech sub-sector, while Hugo Schmidt’s main responsibility lies in the Health Services sub-sector. Amennai Beyeen, with 12 years of experience at global healthcare company Novartis, is responsible for the Biotech and Pharma sub-sectors. The investment team is led by co-founder and CIO Henrik Rhenman.
Under Henrik Rhenman’s helm as CIO, Rhenman & Partners has been running Rhenman Healthcare Equity L/S since its inception in mid-2009. Employing a long-biased long/short equity approach to investing in the global healthcare industry, Rhenman Healthcare Equity L/S has delivered an annualized return of 16 percent since inception through the end of 2023. With €815 million in assets under management as of the end of December, Rhenman Healthcare Equity L/S ranks as one of the largest individual hedge funds in the Nordic hedge fund industry.
